Article Versions Notes

Fedele P, Rizzo A, Landriscina M, Stucci SL, Morritti M, Giuliani F, Moraca L, Cairo G, Ardito R, Giampaglia M, et al. BRCA1 and 2 Mutations and Efficacy of Pembrolizumab-Based Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Real-World Multicenter Analysis. Journal of Clinical Medicine. 2025; 14(24):8854. https://doi.org/10.3390/jcm14248854

Fedele, Palma, Alessandro Rizzo, Matteo Landriscina, Stefania Luigia Stucci, Maria Morritti, Francesco Giuliani, Lucia Moraca, Giuseppe Cairo, Raffaele Ardito, Marianna Giampaglia, and et al. 2025. "BRCA1 and 2 Mutations and Efficacy of Pembrolizumab-Based Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Real-World Multicenter Analysis" Journal of Clinical Medicine 14, no. 24: 8854. https://doi.org/10.3390/jcm14248854

Fedele, P., Rizzo, A., Landriscina, M., Stucci, S. L., Morritti, M., Giuliani, F., Moraca, L., Cairo, G., Ardito, R., Giampaglia, M., Bilancia, D., Melaccio, A., Terenzio, A., Gnoni, A., Licchetta, A., Fumai, F., Lanotte, L., & Gadaleta-Caldarola, G. (2025). BRCA1 and 2 Mutations and Efficacy of Pembrolizumab-Based Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Real-World Multicenter Analysis. Journal of Clinical Medicine, 14(24), 8854. https://doi.org/10.3390/jcm14248854